About TYSABRI

Action may be the best option

TYSABRI® (natalizumab) increases the risk of progressive multifocal leukoencephalopathy (PML). When starting and continuing treatment with TYSABRI, it is important that you discuss with your doctor whether the expected benefit of TYSABRI is enough to outweigh this risk.

TYSABRI has been administered more than 2 million times*

TYSABRI® (natalizumab), an infusion taken every 28 days (for a total of 2 hours), delivers results in many people with relapsing multiple sclerosis (MS).
Before making any treatment choice, it is important to talk with your doctor to make sure whatever decision you make is the right one for you.

*As of June 2014.

TYSABRI is only available through a restricted distribution program called the TOUCH® Prescribing Program

To receive TYSABRI, you must discuss with your doctor the potential benefits and risks, and agree to all of the instructions in the TOUCH Prescribing Program. Before you receive TYSABRI, your doctor or nurse will:

  • Explain the TOUCH Prescribing Program
  • Review and have you sign the TOUCH Prescriber/Patient Enrollment Form

Before every TYSABRI infusion, you will be asked a series of questions to confirm that TYSABRI is still right for you. Call your doctor right away to report any medical problems that keep getting worse and have lasted several days.

WHAT'S NEXT:

Learn about the 3 ways TYSABRI may impact relapsing MS... More >>

 
Open Close

Indication

TYSABRI® (natalizumab) is a prescription medicine used to treat adults with relapsing forms of Multiple Sclerosis (MS). TYSABRI can slow the worsening of symptoms common in people with MS and can decrease the number of flare-ups (relapses). TYSABRI increases the risk of PML. When starting and continuing treatment with TYSABRI, it is important that you discuss with your doctor whether the expected benefit of TYSABRI is enough to outweigh this risk.

Important Safety Information

Please see Full Prescribing Information (PDF) including Boxed Warning and Patient Medication Guide (PDF).

This information is not intended to replace discussions with your healthcare provider.